Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma

NCT04988841 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: MaaT013
DRUG: Ipilimumab
DRUG: Nivolumab
DRUG: MoviPrep
DRUG: Normacol
DRUG: Placebo of Maat013

Sponsor

Assistance Publique - Hôpitaux de Paris